110 (PB098): Efficacy of WNTinib, a novel selective therapeutic for CTNNB1-mutant tumors, in preclinical models of hepatoblastoma

Ugne Balaseviciute; Jordi Abril‐Fornaguera; Júlia Huguet‐Pradell; Eduardo Fernández‐Martínez; Albert Gris‐Oliver; Alexander Rialdi; Agavni Mesropian; Gulay Ulukaya; Danielle M. Hasson; Ieva Keraite; Roser Pinyol; S N Thung; Ernesto Guccione; Josep M. Llovet

doi:10.1016/j.ejca.2024.114633

Related publications

Article2024

FRI-467 Efficacy of WNTinib, a novel selective therapeutic for CTNNB1 mutant tumors, in preclinical models of hepatoblastoma

Ugne Balaseviciute, Jordi Abril‐Fornaguera, Júlia Huguet‐Pradell, Alex Rialdi, Elisa Fernández-Martínez, Albert Gris‐Oliver, Agavni Mesropian, Gulay Ulukaya, Dan Hasson, Ieva Keraite, Roser Pinyol, Swan N. Thung, Ernesto Guccione, Josep M. Llovet

Journal of Hepatology

Article2025

TOP-128-YI Efficacy of WNTinib, a novel selective therapeutic for CTNNB1mutant tumors, in preclinical models of hepatoblastoma

Ugne Balaseviciute, Júlia Huguet‐Pradell, Jordi Abril‐Fornaguera, Elisa Fernández-Martínez, Albert Gris‐Oliver, Roser Pinyol, Alex Rialdi, Agavni Mesropian, Gulay Ulukaya, Dan Hasson, Ieva Keraite, Swan N. Thung, Ernesto Guccione, Josep M. Llovet

Journal of Hepatology

Article2025

Effective therapeutic targeting of <i>CTNNB1</i> ‐mutant hepatoblastoma with <scp>WNTinib</scp>

Ugne Balaseviciute, Júlia Huguet‐Pradell, Jordi Abril‐Fornaguera, Albert Gris‐Oliver, Alex Rialdi, Elisa Fernández-Martínez, Carla Montironi, Vanessa Del Pozo, Peter Houghton, Laura Zanatto, Agavni Mesropian, Ieva Keraite, Swan N. Thung, Carolina Armengol, Pau Sancho‐Bru, Ernesto Guccione, Roser Pinyol, Josep M. Llovet

Article2023

WNTinib is a multi-kinase inhibitor with specificity against β-catenin mutant hepatocellular carcinoma

Alexander Rialdi, Mary E. Duffy, Alex P. Scopton, Frank Fonseca, Julia N. Zhao, Megan Schwarz, Pedro Molina-Sánchez, Slim Mzoughi, Elisa Arceci, Jordi Abril‐Fornaguera, Austin Meadows, Marina Ruiz de Galarreta, Denis Torre, Kyna Reyes, Yan Ting Lim, Felix Rosemann, Z.M. Khan, Kevin Mohammed, Xuedi Wang, Xufen Yu, Manikandan Lakshmanan, Ravisankar Rajarethinam, Soo Yong Tan, Jian Jin,

Article2025

THU-077-YI E7386 enhances lenvatinib’s antitumor efficacy and upregulates ATF4 signalling in preclinical models and human hepatocellular carcinoma

Agavni Mesropian, Albert Gris‐Oliver, Ugne Balaseviciute, Martí Torres-Marcen, Jordi Abril‐Fornaguera, Marta Piqué‐Gili, David Camell, Judit Peix, Elisa Fernández-Martínez, Júlia Huguet‐Pradell, Ieva Keraite, Roger Esteban-Fabró, Takayuki Kimura, Alka A. Potdar, Marina Bárcena‐Varela, Katherine E. Lindblad, Amaia Lujambio, Ernesto Guccione, Swan N. Thung, Daniela Sia, Roser Pinyol, Josep M. Llovet

110 (PB098): Efficacy of WNTinib, a novel selective therapeutic for CTNNB1-mutant tumors, in preclinical models of hepatoblastoma

Abstract

Discussion(0)

Related publications

FRI-467 Efficacy of WNTinib, a novel selective therapeutic for CTNNB1 mutant tumors, in preclinical models of hepatoblastoma

TOP-128-YI Efficacy of WNTinib, a novel selective therapeutic for CTNNB1mutant tumors, in preclinical models of hepatoblastoma

Effective therapeutic targeting of <i>CTNNB1</i> ‐mutant hepatoblastoma with <scp>WNTinib</scp>

WNTinib is a multi-kinase inhibitor with specificity against β-catenin mutant hepatocellular carcinoma

THU-077-YI E7386 enhances lenvatinib’s antitumor efficacy and upregulates ATF4 signalling in preclinical models and human hepatocellular carcinoma